A shares: Announcement express, on Tuesday, eight companies issued important announcements

1. Tigerpharma: First repurchase of 16,600 shares TigerPharma announced that on February 15, 2022, the company first repurchased 16,600 shares of the company’s shares, with A total transaction amount of 1,634,800 yuan (excluding transaction costs).2. Longsheng Technology:A patent Licensing Agreement has been signed between Longsheng New Energy and Kuroda Precision Manufacturing Co., LTD., a subsidiary of Longsheng FASTEC Corporation, and Kuroda Precision Manufacturing Co., LTD.Kuroda Seiko has licensed Its unique “Glue FASTEC®” intellectual property and proprietary technology to Longsheng New Energy to use in its new energy drive motor core products.3. CCCC performance Bulletin: Net profit in 2021 increased by 17.92% year on year. CCCC issued 2021 annual performance bulletin, realizing operating revenue of 5.089 billion yuan, up 26.75% year on year.Net profit reached 150 million yuan, up 17.92% year on year.Small financial note: Q3 net profit of 34.63 million yuan, according to the calculation, Q4 net profit of 66.13 million yuan, a sequential growth of 91%.Ambler announced 2021 annual performance announcement, the company in 2021 to achieve total operating revenue of 2.311 billion yuan, compared with 2020 growth of 19.50%;Net profit attributable to shareholders of listed companies is 315 million yuan, an increase of 14.18% compared with 2020.5. Voriconazole for injection: Voriconazole for injection received marketing authorization from the UK Pharmaceutical Regulatory Authority (MHRA).6. China Pacific Insurance: Original insurance revenue totaled 76.895 billion Yuan in January China Pacific Life Insurance Co., LTD., a subsidiary of the company, announced that the cumulative revenue of original insurance business in January was 55.884 billion yuan, down 1.1% year on year;China Pacific Property and Casualty Insurance Co., LTD., a subsidiary of the company, accumulated original insurance revenue of 21.011 billion yuan, up 12.7% year on year.7, Osai Kang: ASKC202 tablets approved clinical trial announcement, subsidiary new drug ASKC202 tablets approved clinical trial notice.8. Biology of Yuan DongQuasi 245 million yuan set YuanDong biological industry fund announcement, the company intends to participate in is set up in suzhou, keep one venture investment partnership (limited partnership), the fund’s focus on health industry, focused on biological medicine field, focus on innovation in medicine, biological medicine, the other can be invested in medical equipment, precision medical, pharmaceutical/medical technology services or big health sectors such as technology platform.The fund size is 500 million yuan, of which 245 million yuan is subscribed by the company.

Leave a Reply

Your email address will not be published.